Trial Profile
Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs INO 4800 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Inovio Pharmaceuticals
- 04 Mar 2022 Status changed from active, no longer recruiting to completed.
- 25 Jan 2022 Results published in the Journal of Infectious Diseases
- 12 Oct 2021 According to an Inovio Pharmaceuticals Media Release , data from this trial is available in the online preprint publication in MedRxiv